
Sign up to save your podcasts
Or


Patients with chronic kidney disease often have a multitude of comorbidities which may present challenges in diagnosis, treatment, and management. In addition, the limitations of currently available treatments may reduce the opportunity for effective improvements in their quality of life. But clinical trial data are emerging, and our understanding about the underlying mechanisms of glomerulonephritis and sclerosis is growing. Find out how these advances could lead to improved outcomes in patients with IgAN, FSGS, and AAV.
=
By ReachMD4.3
33 ratings
Patients with chronic kidney disease often have a multitude of comorbidities which may present challenges in diagnosis, treatment, and management. In addition, the limitations of currently available treatments may reduce the opportunity for effective improvements in their quality of life. But clinical trial data are emerging, and our understanding about the underlying mechanisms of glomerulonephritis and sclerosis is growing. Find out how these advances could lead to improved outcomes in patients with IgAN, FSGS, and AAV.
=